MedTrace Logo

RNActive® Rabies Vaccine (CV7201) in Healthy Adults

NCT02241135 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2018-10-29

No results posted yet for this study

Summary

The purpose of this trial is to assess the safety and immunogenicity of an investigational RNActive® rabies vaccine (CV7201) in healthy adults.

Conditions

  • Rabies

Interventions

BIOLOGICAL

CV7201 mRNA

CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.

Sponsors & Collaborators

  • CureVac

    lead INDUSTRY

Principal Investigators

  • Franz-Josef Falkner von Sonnenburg, MD · Ludwig-Maximilians - University of Munich

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-02-08
Completion
2018-02-08

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02241135 on ClinicalTrials.gov